LONDON – Vernalis plc has taken the decisive step in casting off its biotech roots, announcing a £65.9 million (US$103.8 million) fundraising that will enable it to enter the U.S. prescription drug market and also catapults the company's market capitalization from £20 million to £100 million. Read More
LONDON – A new understanding of interactions between bacterial proteins could lead to novel antibiotics that halt the discharge of toxins into host cells.
Read More
With regulatory filings for its prostate cancer therapy, Alpharadin (radium-223 chloride), expected in mid-2012, Algeta ASA is seeking up to NOK260 million (US$45.4 million) in a private placement to enable it to establish a commercial base in the U.S. in advance of a product launch and to continue research and development of its second line of alpha emitters, based on thorium-227. Read More
Pharnext SAS has unveiled €8 million (US$10.5 million) in new funding, which will enable the network pharmacology company to take its second drug development program, in Alzheimer's disease, into the clinic this year.
Read More
LONDON – Pricing pressures, piled on top of R&D productivity problems, have cut the return on investment and left many asking if developing new drugs is worth the risk.
Read More
LONDON – The European Medicines Agency (EMA) has published guidelines describing how it wants to see the consequences of genetic variability between patients integrated into the investigation of pharmacokinetics of drugs in development.
Read More
• Gedeon Richter plc, of Budapest, Hungary, and Forest Laboratories Inc., of New York, reported top-line results from a Phase III trial of cariprazine (RHG-188), an antipsychotic agent, in patients with acute mania associated with bipolar I disorder. For the primary endpoint, the Young Mania Rating Scale, data showed cariprazine-treated patients experienced significant improvements in symptoms compared to those in the placebo arm, observed as early as day five of treatment and at each subsequent time point studied.
Read More